Kailera Therapeutics, Inc.

Filing Date

Apr 16, 2026

Transaction Date

Apr 16, 2026

Accession Number

0001193125-26-159772

Form Type

3

Footnotes

1. (F1)Each share of the Issuer's Series A-1 Preferred Stock is convertible, at the option of the holder, into shares of the Issuer's Common Stock on a 1:1 basis and will automatically convert upon the closing of the Issuer's initial public offering. These securities have no expiration date.
2. (F2)Each share of the Issuer's Series B Preferred Stock is convertible, at the option of the holder, into shares of the Issuer's Common Stock on a 1:1 basis and will automatically convert upon the closing of the Issuer's initial public offering. These securities have no expiration date.
3. (F3)Represents shares of the Issuer's Series A-1 Preferred Stock and Series B Preferred Stock held directly by BCLS Fund IV Investments, LP ("BCLS Fund IV Investments").
4. (F4)Dr. Koppel is a Partner of Bain Capital Life Sciences Investors, LLC ("BCLSI"). BCLSI is the ultimate general partner of BCLS Fund IV Investments. As a result, Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. Dr. Koppel disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.